Luke James Vano

Luke James Vano

Auto-generated profile, based on publicly available information

Luke James Vano

Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London , London , SE5 8AF

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2019 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
RMRobert A. McCutcheon
Robert A. McCutcheon
TPToby Pillinger
Toby Pillinger
YMYuya Mizuno
Yuya Mizuno
AMAdam Montgomery
Adam Montgomery
HPHaridha Pandian
Haridha Pandian
OHOliver D. Howes
Oliver D. Howes

26 June 2024 in Biological Psychiatry
Verified
Journal Article
Open access
LVLuke J. Vano
Luke J. Vano
RMRobert A. McCutcheon
Robert A. McCutcheon
Grazia RutiglianoGrazia Rutigliano
Grazia Rutigliano
SKStephen J. Kaar
Stephen J. Kaar
VFValeria Finelli
Valeria Finelli
OHOliver D. Howes
Oliver D. Howes
Striatal hyperdopaminergia is implicated in the pathoetiology of schizophrenia, but how this relates to dopaminergic midbrain activity is unclear. Neuromelanin (NM)-sensitive magnetic resonance imaging provides a marker of long-term dopamine function. We examined whether midbrain NM-sensitive magnetic resonance imaging contrast-to-noise ratio (NM-CNR) was higher in people with schizophrenia than in healthy control (HC) participants and whether this correlated with dopamine synthesis capacity. One hundred fifty-four participants (schizophrenia group: n = 74, HC group: n = 80) underwent NM-sensitive magnetic resonance imaging of the substantia nigra and ventral tegmental area (SN-VTA). A subset of the schizophrenia group (n = 38) also received [18F]-DOPA positron emission tomography to measure dopamine synthesis capacity (Kicer) in the SN-VTA and striatum. SN-VTA NM-CNR was significantly higher in patients with schizophrenia than in HC participants (effect size = 0.38, p = .019). This effect was greatest for voxels in the medial and ventral SN-VTA. In patients, SN-VTA Kicer positively correlated with SN-VTA NM-CNR (r = 0.44, p = .005) and striatal Kicer (r = 0.71, p < .001). Voxelwise analysis demonstrated that SN-VTA NM-CNR was positively associated with striatal Kicer (r = 0.53, p = .005) and that this relationship seemed strongest between the ventral SN-VTA and associative striatum in schizophrenia. Our results suggest that NM levels are higher in patients with schizophrenia than in HC individuals, particularly in midbrain regions that project to parts of the striatum that receive innervation from the limbic and association cortices. The direct relationship between measures of NM and dopamine synthesis suggests that these aspects of schizophrenia pathophysiology are linked. Our findings highlight specific mesostriatal circuits as the loci of dopamine dysfunction in schizophrenia and thus as potential therapeutic targets.

5 September 2025 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
LVLuke J. Vano
Luke J. Vano
RMRobert A. McCutcheon
Robert A. McCutcheon
JSJan Sedlacik
Jan Sedlacik
GRGrazia Rutigliano
Grazia Rutigliano
SKStephen J. Kaar
Stephen J. Kaar
OHOliver D. Howes
Oliver D. Howes
Iron—the most abundant magnetic brain substance—is essential for many biological processes, including dopamine and myelin synthesis. Quantitative susceptibility mapping (QSM) MRI has recently linked altered subcortical magnetic susceptibility (χ) to schizophrenia. Since χ is increased by iron and decreased by myelin, abnormal levels of either could underlie these QSM differences. In white matter tracts, magnetic susceptibility anisotropy (δχ) serves as a myelin-specific marker that is insensitive to iron content. To clarify the origin of case-control χ differences, we employed QSM in 85 individuals with schizophrenia, from first-episode mental health teams, and 86 healthy controls. A subset also underwent diffusion tensor imaging (DTI) to calculate subcortical tissue mean diffusivity, which inversely correlates with myelin concentration and fractional anisotropy. White matter δχ was calculated by combining QSM and DTI. Schizophrenia was associated with lower subcortical χ (d = −0.36, p = 0.023). This was significant in the caudate nucleus (d = −0.37, p = 0.037), putamen (d = −0.36, p = 0.037), globus pallidus (d = −0.57, p = 0.001), and SN-VTA (as previously reported). Additionally, schizophrenia was linked to higher subcortical mean diffusivity (d = 0.44, p = 0.018), and lower white matter δχ (d = −0.37, p = 0.047). These findings suggest that both subcortical iron and brain myelin levels are lower in schizophrenia. By comparing our voxelwise χ maps with postmortem gene expression data, we reveal that regions with lower subcortical χ in schizophrenia are enriched for oligodendrocyte-related genes (p < 0.001). As oligodendrocytes are both the most iron-rich brain cells and essential for myelin synthesis, our results implicate oligodendrocyte dysfunction in schizophrenia pathophysiology.

1 September 2025 in American Journal of Psychiatry
Verified
Journal Article
Open access
LVLuke James Vano
Luke James Vano
RMRobert Ali McCutcheon
Robert Ali McCutcheon
JSJan Sedlacik
Jan Sedlacik
SKStephen John Kaar
Stephen John Kaar
GRGrazia Rutigliano
Grazia Rutigliano
OHOliver David Howes
Oliver David Howes
Neuroimaging studies have independently associated schizophrenia with low iron and elevated dopamine synthesis. While preclinical research demonstrates that midbrain iron deficiency leads to striatal hyperdopaminergia, this relationship has not been studied in schizophrenia. The authors conducted a case-control study to examine differences in tissue magnetic susceptibility, a marker of brain iron, and correlated these with striatal dopamine synthesis capacity. Magnetic susceptibility in the substantia nigra and ventral tegmental area (SN-VTA) was measured using quantitative susceptibility mapping (QSM) MRI in 159 participants (control subjects, N=80; early-course schizophrenia, N=79, including patients who were antipsychotic-naïve or antipsychotic-free). Because magnetic susceptibility is increased by neuromelanin and reduced by myelin, neuromelanin-sensitive MRI (NM-MRI) and diffusion tensor imaging (DTI) were employed to investigate the influence of neuromelanin and myelin on the QSM findings in 99 participants (control subjects, N=38; schizophrenia patients, N=61). Dopamine synthesis capacity (Ki cer) was then assessed with [18F]-DOPA positron emission tomography in 40 people from the schizophrenia group to test whether low SN-VTA magnetic susceptibility was related to high striatal Ki cer. SN-VTA magnetic susceptibility was lower in patients with schizophrenia than in control subjects (d=-0.66, 95% CI=-0.98, -0.34). This difference remained significant in analyses controlling for mean diffusivity (a DTI measure inversely correlating with myelin concentration) and NM-MRI contrast-to-noise ratios. SN-VTA magnetic susceptibility was significantly inversely correlated with striatal Ki cer, independent of mean diffusivity and NM-MRI contrast-to-noise ratios (r=-0.44). In both analyses, the strongest effects were observed in the ventral SN-VTA. These findings suggest that lower levels of non-neuromelanin-bound iron in the SN-VTA contribute to striatal hyperdopaminergia in schizophrenia. Further investigation is warranted to understand the role of low iron in schizophrenia and its potential as a treatment target.

21 October 2025 in Biological Psychiatry
Verified
Journal Article
Open access
OHOliver D. Howes
Oliver D. Howes
LVLuke J. Vano
Luke J. Vano
APAlice E. Petty
Alice E. Petty
GRGrazia Rutigliano
Grazia Rutigliano
EHEls F. Halff
Els F. Halff
RMRobert A. McCutcheon
Robert A. McCutcheon
Schizophrenia remains a leading cause of disability globally. Elevated striatal dopamine (DA) synthesis capacity is a hallmark of its pathophysiology, but it is unknown whether this can be reduced and whether such reductions lead to symptom improvement. TAAR1 may regulate dopaminergic function, and ulotaront (SEP-363856), a TAAR1 agonist, offers a potential novel treatment strategy. We conducted combined translational preclinical and clinical tests of mechanism studies. Preclinical work involved TAAR1 knockout (KO) and wild-type (WT) mice (N = 27), as well as ex vivo striatal brain slices. In a phase 1 open-label trial, 22 patients with symptomatic schizophrenia (mean age = 32.5 years; 72.7% male) received 14 days of adjunctive ulotaront treatment. DA synthesis capacity (Ki) was measured using [18F]-DOPA positron emission tomography in animals and humans. DA release in brain slices was assessed using fast-scan cyclic voltammetry. TAAR1-KO mice showed significantly higher striatal Ki than WT controls (p < .05). Ulotaront reduced evoked DA release in brain slices after single (p < .0005) and repeated (p < .005) stimulation. In patients, ulotaront significantly reduced striatal Ki (p < .01), particularly in the putamen. Reductions in Ki correlated with improvements in positive symptoms (r = 0.5, p < .05) but not with changes in negative or total symptoms. The most common adverse events were somnolence and dizziness. TAAR1 regulates DA synthesis and release. Adjunctive ulotaront reduces presynaptic DA function and psychotic symptoms in schizophrenia. These findings support TAAR1 as a promising target for treating antipsychotic nonresponsive schizophrenia and other dopaminergic disorders.

17 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
LVLuke James Vano
Luke James Vano
JSJan Sedlacik
Jan Sedlacik
RCRichard Carr
Richard Carr
BBBernard Roch Bukala
Bernard Roch Bukala
OHOliver David Howes
Oliver David Howes
RMRobert Ali McCutcheon
Robert Ali McCutcheon
Objective: The pathophysiology of psychosis remains unclear. Preclinical, postmortem, and imaging evidence implicates iron and neuromelanin, but the consistency and magnitude of effects are uncertain. We aimed to characterise brain iron and neuromelanin alterations in psychosis through a systematic review and meta-analysis of iron-sensitive MRI and neuromelanin-sensitive MRI (NM-MRI) studies. Methods: We searched EMBASE, PubMed, and PsycINFO from inception to October 31, 2025, for case-control studies using iron-sensitive MRI or NM-MRI in patients with psychosis. We used random-effects models to calculate effect sizes (Hedges g) and meta-regressions to examine clinical confounders. The primary outcomes included effect sizes for NM-MRI and iron-sensitive MRI measures: transverse relaxation rate (R2), effective relaxation rate (R2*), and quantitative susceptibility mapping (QSM). Results: Twenty-seven reports, including 879 individuals with psychosis and 813 controls, were analysed. Meta-analyses were conducted across the caudate nucleus, putamen, globus pallidus, thalamus, and substantia nigra. In psychosis, R2* was significantly lower across all examined regions (g= -0.27 to -0.40), QSM values were lower in the substantia nigra (g= -0.61; 95% CI, -0.84 to -0.38), and R2 was lower in the caudate nucleus (g= -0.30; 95% CI, -0.56 to -0.04). NM-MRI values in the substantia nigra were significantly higher (g= 0.39; 95% CI, 0.23 to 0.55), though this effect strongly correlated with chlorpromazine daily equivalent dose (β= 0.001; 95% CI, 0.0003 to 0.0018), suggesting medication-related effects. Conclusions: Psychosis is associated with lower subcortical iron-sensitive MRI values. This was most marked in the substantia nigra, where NM-MRI values, which index neuromelanin-bound iron in dopamine neurones, were significantly higher. This suggests that while subcortical iron is overall lower in psychosis, neuromelanin-bound iron is increased within dopamine neurones. Investigating the mechanisms underlying iron alterations may provide new treatment targets.